Aequus Pharmaceuticals (AQSZF)

[BioSpecialist]

Interview with Ceo Doug Janzen
http://business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canada

James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?

Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.


James West: Sure. Have you built a pharmaceutical company before, Doug?

Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.



Sep 19/16 Janzen, Doug Direct Ownership Common Shares 10 - Acquisition in the public market 9,000 $0.290

Sep 19/16 Janzen, Doug Direct Ownership Common Shares 10 - Acquisition in the public market 1,000 $0.285

Sep 13/16 Janzen, Doug Direct Ownership Common Shares 15 - Acquisition under a prospectus 830,300 $0.300